Last reviewed · How we verify
National Marrow Donor Program — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| HPC, Cord Blood | HPC, Cord Blood | marketed | Cell therapy; hematopoietic stem cell transplant | Oncology; Hematology |
Therapeutic area mix
- Oncology; Hematology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for National Marrow Donor Program:
- National Marrow Donor Program pipeline updates — RSS
- National Marrow Donor Program pipeline updates — Atom
- National Marrow Donor Program pipeline updates — JSON
Cite this brief
Drug Landscape (2026). National Marrow Donor Program — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/national-marrow-donor-program. Accessed 2026-06-10.